Recombinant bovine basic fibroblast growth factor (r-bFGF) was adopted to treat xerophthalmia patients within one month after phacoemulsification, which could promote basic tear secretion, subjective dry eye sensation score, and corneal fluorescence staining score [28, 29]. This evidence concerns the gene FGF2 and Keratoconjunctivitis sicca.